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  ABSTRACT 
Objective: The purpose of this case study is to inform athletic trainers of a systematic disease 
not common in our patient population. Background: The athlete, a twenty-one YO, 160 lb, 69 
inch female NCAA-I collegiate soccer goalie presented with complaint of bilateral elbow and 
knee joint pain and stiffness along with tender red itchy bumps on the anterior aspect of her 
shins. The athlete had flu-like symptoms and a URI prior to this complaint. The athlete has a 
history of anemia, mononucleosis, and streptococcal. Differential Diagnosis: Rheumatoid 
arthritis, lymphoma, HIV/aids, erythema nodosum, lupus, Lyme disease. Treatment: The athlete 
sought out multiple medical evaluations to treat the condition; including the ER. Multiple tests 
were run to rule out strep among other things. The athlete received various prescriptions to treat 
fatigue, infection, inflammation, and pain. Uniqueness: Erythema nodosum is a rare disorder 
that affects approximately 1-5 per 100,000 people per year. Typically seen in the female 25-40 
year old population, the cause is usually idiopathic; however, the most common cause is 
streptococcal pharyngitis.
1-6
 Conclusion: This case demonstrates the awareness of a systematic 
condition that could be present within the athletic population. With this information, clinicians 
can better diagnose and treat erythema nodosum along with awareness of etiologies causing the 
condition. Key Words: Erythema nodosum
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CHAPTER 1 
INTRODUCTION 
 Erythema nodosum (EN) is a common type of septal panniculitis that occurs when the 
hypodermal septa becomes inflamed with neutrophils.
1
 Due to a reactive process the septa in 
subcutaneous fat filters with inflammatory cells and produces reactive oxygen causing localized 
edema.
1-6
 This hypersensitive response can be caused by varying antigens, but in 1/3 of all cases 
is reported as idiopathic.
7,8
 Most commonly seen in females, in 83% of cases, during their 
twenties to forties, EN presents as round red tender nodules bilaterally on the anterior tibia.
3
 
Nodules generally resolve within 4-6 weeks after onset without signs of scarring, atrophy, or 
ulceration.
7,8
  
 Association with infections, drugs, chronic inflammatory diseases, malignancy, and a 
number of disease processes can cause the sudden acute onset of EN.
3,6-8
 Patients may present 
with fever, chills, malaise, arthralgia, and arthritis in conjunction with anterior tibia nodules.
4,6,9
 
Diagnostic testing can consist of a complete blood count (CBC), erythrocyte sedimentation rate 
(ESR), throat culture, chest x-ray, tuberculin test, antistreptolysin O (ASO), serum 
immunoglobulins, and biopsy.
3,6,7,9-11
  
 If the cause of outbreak is known, treatment is to remove the underlying trigger. 
However, in other cases, the use of non-steroidal anti-inflammatories (NSAIDs), potassium 
iodide (KI), colchicine, corticosteroids, and rest will help alleviate symptoms.
3,6-9
 Recurrences 
occur more commonly if the etiology is unknown and are estimated in 33-41% of cases.
3
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CHAPTER 2 
CASE REVIEW 
 A 21 YO female NCAA-I collegiate soccer goalie presented with complaint of bilateral 
elbow and knee joint pain and stiffness along with tender red itchy bumps on the anterior aspect 
of her shins that did not follow a dermatome pattern (Figure 1). The previous week, she 
complained of flu-like symptoms that resolved within three days but did not see a physician for 
symptoms. The current symptoms began approximately three to four days from the onset of joint 
pain and swelling. She presented in the athletic training room walking with locked knees and was 
unable to actively flex her elbows past 90 degrees due to pain; however, passively she had full 
range of motion with mild pain at the end points. A family history of lipoma and breast cancer 
exists. Athlete also has a history of anemia diagnosed in 2009, mononucleosis diagnosed in 
2009, and multiple diagnosis of streptococcal between 2006 and 2008 that occurred once a year; 
she is not on any prescription drugs or oral contraceptives at this time.  
 The athlete was referred to her family physician for evaluation the day she presented to 
the athletic training room. A complete blood count (CBC), metabolic panel, erythrocyte 
sedimentation rate (ESR), and antistreptolysin O (ASO) test performed did not show 
abnormalities. She was prescribed 200 mg of Celebrex for pain and arthralgia taken once daily 
for six days and told the symptoms should resolve in 24-48 hours. HIV/aids were ruled out at this 
time due to lack of risky history, Lyme disease because of the rash appearance, and lymphoma 
due to normal WBC count. Two days later, the athlete was treated at the emergency room due to 
worsening symptoms. She admitted symptoms related to an upper respiratory infection (URI) 
two weeks prior to the flu-like symptoms but denied continuing symptoms. She did not see a 
physician for any of these symptoms she experienced. Athlete reported stiffness and decreased 
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range of motion in both knees and elbows. No signs of joint erythema, warmth, or swelling were 
noted at the ER.  
An ECG, urine culture, ASO test, and another CBC/ESR were ordered. The ECG showed 
normal clear lungs and normal heart size, cloudiness of urine, and a negative strep test was 
concluded. The CBC showed low hemoglobin and her ESR was high (Table 1). She was 
diagnosed with erythema nodosum, prescribed 800 mg ibuprofen TID PRN for pain and follow 
up with her primary physician in one week. At the follow-up, the athlete’s labs revealed a trace 
of ketone and increased ESR. The blood culture, urine culture, ANA, rheumatoid arthritis factor, 
and strep tests were all within normal limits. Negative RAF ruled out rheumatoid arthritis and 
normal ANA tests suggested she did not have lupus. 
Test Norms First Visit (2-4-13) ER Visit (2-6-13) Follow-Up (2-11-13) 
CBC WBC 4.5 - 10 x10E3/uL 6.7 6.2  - 
  RBC 
3.7 - 5.2 
x10E6/uL 4.38 4.08  - 
  Hg 12 - 16 g/dL 12.4 11.9  - 
  Hct 35 - 47 % 36.60% 35.30%  - 
Metabolic  Glucose 65 - 99 mg/dL 85 92  - 
Panel Albumin 3.5 - 5.5 g/dL 4.1 4.2  - 
  Globulin 1.5 - 4.5 g/dL 3 3.2  - 
ESR 0 - 32 mm/hr 9 36 53 
ASO Negative Negative Negative Negative 
Urinalysis Clarity Clear  - Cloudy Clear 
  Color Yellow  - Dark Yellow Yellow 
  Specific Gravity 1.005 - 1.030  - 1.032 1.025 
  pH 4.5 - 8  - 6.5 6 
  Occult Blood Negative  - Negative Negative 
  Glucose Negative  - Negative Negative 
  Ketones Negative  - Trace Trace 
  Protein 40 - 80  - 30 Negative 
  Leukocytes Negative  - Moderate Negative 
ECG Heart Size WNL  - WNL  - 
  Lungs Clear  - Clear  - 
  
Spine 
Curvature WNL  - Scoliosis -  
RAF .0 - 13.9  -  - 11.5 
ANA Negative  - -  Negative 
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Table 1. Diagnostic Testing 
 
Despite medications prescribed, the athlete’s pain continued to worsen and she was 
unable to walk without pain. Swelling appeared around her knees and elbows; however, she no 
longer has range of motion limitations. Her family physician diagnosed her with erythema 
nodosum and pyrexia; she was prescribed 500 mg of penicillin QID for ten days and 10 mg of 
prednisone for 30 days to treat infection and inflammation. Diagnosis of pyrexia could be caused 
by the amount of inflammation she presented with and as a side effect of EN. Although the 
diagnosis did not change, her treatment plan was altered due to worsening symptoms and no 
alleviation of pain. At the fourteen-day follow-up after diagnosis, the athlete complained of 
fatigue and joint stiffness; however, the lesions disappeared and left mild scarring (Figure 2). 
Lastly, she was prescribed vitamin D for fatigue and advised to follow-up as needed. 
                                              
Figure 1. Lesions of bilateral anterior            Figure 2. Resolution of lesions  
tibia two days after formation                                                    two weeks after diagnosis 
 
 Since recovering from diagnosis, athlete has no signs or symptoms of further illnesses. A 
follow-up appointment was not needed due to alleviation of symptoms. Lesions resolved two 
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weeks and arthralgia persisted for two months after diagnosis. She was back to feeling normal 
ten weeks after diagnosis but chose not to return to activity such as leisure running and 
intermural soccer until four months after diagnosis (Table 2). 
Timeline Events 
1/21/2013 Experienced flu-like and URI symptoms - did not seek medical attention 
2/1/2013  Joint pain and swelling 
2/4/2013 
Noticed tender red itchy bumps on bilateral anterior shins with symptoms of 
bilateral knee and elbow arthralgia, presented to the ATR and referred to 
family physician - CBC, metabolic panel, ESR, and ASO WNL. Prescribed 
200 mg Celebrex; ruled out lymphoma, HIV/aids, and Lyme disease. 
2/6/2013 
ER visit due to worsening symptoms - urinalysis, ASO, CBC, ESR, and 
ECG ordered. Low hemoglobin showed in CBC, high ESR, and all other 
tests WNL. Prescribed 800 mg ibuprofen.  
2/11/2013 
Follow-up with PCP - urinalysis showed trace of ketones, elevated ESR, 
and negative RAF, blood culture, ANA, and ASO.  Prescribed 500 mg 
Penicillin and 10mg Prednisone; ruled out RA and Lupus.  
2/25/2013 
Follow-up with PCP - complaints of fatigue and joint stiffness, lesions 
resolved leaving mild scarring. Prescribed Vitamin D, follow-up as needed. 
4/1/2013 Arthralgia symptoms resolved 
4/15/2013 Began feeling "normal" 
5/27/2013 Returned to activity 
 
Table 2. Timeline of Events 
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CHAPTER 3 
DIFFERENTIAL DIAGNOSIS 
The following is a list of the possible diagnosis and their key symptoms (Refer to Table 3): 
Rheumatoid Arthritis
12 
 Joint Pain/Stiffness/Inflammation 
 Decreased Range of Motion 
 Fever 
 Tenderness 
 Rash 
 Fatigue 
 Loss of Appetite 
 Pain Over Several Joints – Symmetrical Pattern 
Rheumatoid arthritis was ruled out to do a negative rheumatoid factor and ANA. 
Lymphoma
13 
 Fever 
 Night Chills 
 Weight Loss 
 Rash/Itching 
 Chest/Lower Back Pain 
Lymphoma was ruled out due to lack of symptoms that coincided with the illness.  
HIV/aids
14 
 Fatigue 
 Fever 
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 Sore Throat 
 Swollen Glands 
 Headache 
 Muscle/Joint Aches and Pains 
 Red or Brown Blotches Under Skin 
HIV/aids were ruled out due to lack of risky history such as blood transfusion and sexual 
behavior. 
Erythema nodosum
4,6,9 
 Malaise 
 Flu-like Symptoms 
 Joint Pain 
 Red Tender Bumps on Anterior Tibia (Bilateral) 
Erythema nodosum was diagnosis due to symptoms; especially that of the bilateral anterior shin 
lesions. 
Lupus
15 
 Extreme Fatigue 
 Headache 
 Fever 
 Photosensitivity 
 Painful/Swollen Joints 
 Abnormal Blood Clotting 
 Anemia 
 Pleurisy 
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Lupus was ruled out after a negative ANA test as well as symptoms did not correspond with 
athlete’s complaints. 
Lyme disease
16
 (Figure 3) 
 Flu-like Symptoms 
 Joint Pain 
 Fatigue 
 Rash (“Bulls-eye” Appearance) 
Lyme disease ruled out because athlete does not live in an area of high risk, no history of tick 
bite, and her rash does not have the “bulls-eye” appearance. 
 
Figure 3. Lyme disease “Bulls-eye” rash.16 
 
 
Joint 
Pain 
Decreased 
ROM Inflammation Fever Rash/Lesions 
Flu-like 
Symptoms Anemia 
Rheumatoid 
Arthritis X X X X X X   
Lymphoma       X X X   
HIV/Aids X     X X     
Erythema 
Nodosum X   X X X X   
Lupus X     X     X 
Lyme 
Disease X       X X   
 
Table 3. Differential Diagnosis 
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CHAPTER 4 
DISCUSSION 
 Based on the individual’s previous history of an upper respiratory infection and flu-like 
symptoms prior to being diagnosed with EN, these are assumed to be the underlying trigger. 
However, due to worsening of symptoms after the athlete was prescribed penicillin, the drug 
could also be a possible cause. The athlete states her lesions resolved within two weeks and 
symptoms within six weeks of diagnosis. The condition typically resolves on its own in 3-6 
weeks. Patients are treated symptomatically with NSAIDs, rest, and elevation.
3,7
 She was able to 
discontinue the prednisone after the first dose. She does not report complications after being 
asymptomatic nor has EN recurred.  
 The athlete’s symptoms were concurrent with those associated with erythema nodosum 
including flu-like symptoms, fatigue, arthralgia, and nodules on bilateral anterior tibia. An 
extensive history of streptococcal and recent URI along with her demographics predisposed her 
to an occurrence of EN. Streptococcal and upper respiratory infections can account for 28-44% 
of EN cases
 
with a female to male ratio of 4-5:1 in all cases.
3
 
 Several diagnostic tests such as CBC, ANA, urinalysis, and ESR should be performed to 
help rule out other possible diagnosis and/or causes of EN (Table 3). A CBC test is a generalized 
test of a patient’s health status that can be used to diagnose varying conditions and diseases such 
as anemia, infection, leukemia, bone marrow disorders, and lymphoma, to name a few. White 
blood cells (WBC), red blood cells (RBC), and platelets are evaluated in a blood sample. Any 
elevation or depression of data outside the norm is considered a red flag.
17
 Antinuclear 
antibodies (ANA) test was performed under the suspicion of inflammation that may be due to an 
autoimmune illness such as Raynaud’s phenomenon, rheumatoid arthritis, and lupus. ANAs can 
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inhibit the body to attack itself mistaking normal proteins as dangerous.
18
 More commonly used 
to screen for lupus, if ANAs are present this may suggest a diagnosis of the disease.
19
 Physical 
features as well as contents of a urinalysis can be evaluated for diagnosis of infection or 
inflammation of the kidneys. The specimen shows levels of pH, glucose, ketones, protein, nitrite, 
WBC, RBC, bacteria, and concentration. Abnormalities suggested an infection, dehydration, 
hematuria (red blood in urine), liver disease, or breakdown of muscle.
20
 ESR is evaluated with a 
blood sample that will indirectly measure the amount of inflammation in the body. This test, if 
abnormal, can diagnose some illnesses such as: anemia, lymphoma, lupus, rheumatoid arthritis, 
kidney disease, pregnancy, and thyroid disease. However, other testing is advised for abnormal 
findings.
21
 
 If symptoms do not resolve in 4-6 weeks, other testing may be performed to further 
diagnose the cause of EN. Tests should be conducted to rule out sarcoidosis, tuberculosis, 
Behcet’s disease, Leprosy, several types of STIs, and other systematic diseases that may lead to 
EN. Other causes can be excluded after collecting a biopsy of the infected area; however, a 
biopsy is not commonly performed unless the lesions do not regress.
3,6,7,9-11
 In this case a further 
testing was not performed because symptoms were alleviated. The etiology of EN is ruled 
uncertain in 37-60% of cases despite medical testing and labs.
7
 
 In 15-40% of all cases, EN presents as an early sign of infection, connective tissue 
disease and/or inflammatory disorder.
6
 Of these cases, patients typically present with an elevated 
ESR and C-reactive protein levels seen by CBC testing.
3,6
 The athlete in this case study did not 
report development of these conditions after diagnosis of EN; however, she presented with an 
elevated ESR that increased from her ER visit to the fourteen-day follow-up.  An elevated ESR 
and cloudiness of urine sample shows presence of inflammation in the body.
20,21
 Labs may show 
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leukocytosis by a WBC count generally greater than 10,000 per mm.
3
 Leukocytosis can be 
present due to an increase in neutrophil count, lymphocyte count, eosinophilic granulocyte count, 
basophilic granulocyte count, or immature cells.
22
 In this case, the athlete’s WBC count was 
below 10,000 per mm, therefore she did not present with leukocytosis.  
 Patients may also have a higher percentage of reactive oxygen intermediates (ROIs) that 
are produced by activated neutrophils in peripheral blood. ROIs contribute to the activity of 
phagocytes, regulation of signal transduction and gene expression, and the oxidative damage to 
the nucleic acids; proteins; and lipids.
23
 ROIs utilize effects of the oxidate and create tissue 
damage and inflammation. Inflammation is proposed to collect in the anterior shins due to the 
combination of arterial supply and gravitational effects of the venous system.
7
 This 
distinguishing location on the shins makes for diagnosis of EN.
4
 
 The incident rate of EN is 1-5 cases /100,000 per year.
2,4,5
 Diagnosis can be caused by 
infections such as streptococcal, sarcoidosis, autoimmune disorders, irritable bowel disease, or 
medications such as oral contraceptives. In some cases, such as sarcoidosis (disease of unknown 
cause leading to inflammation of organs); the presence of EN shows for an improved prognosis.
5
 
Most cases in the United States are diagnosed during the first half of the year when streptococcal 
is at its highest incident rate.
7
 
 Erythema nodosum is a form of panniculitis, an inflammation of the subcutaneous fat 
layer.
3-6
 EN can be caused by hypersensitivity to antigens such as beta-haemolytic streptococcal.
5
 
Lesions form on the anterior shin and are typically 1-5 cm in diameter. The lesions begin to 
flatten as the bumps resolve and heal in a bruise-like appearance.
3,5
 Patients may experience new 
lesions for up to two months, however, they should slowly begin to resolve after two weeks.
3,7
 
Symptoms such as arthralgia may last for up to two years after resolution of lesions.
3
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 Treatment of EN is symptomatic usually consisting of rest, elevation, and the use of 
NSAIDs for alleviation of pain and controlling edema.  If caused by a known etiology, such as 
oral contraceptives or other medications, the patient should discontinue use. For infections, such 
as streptococcal, medications may be prescribed to treat the illness. Potassium iodide (KI) may 
be administered if lesions persists longer than six weeks.
3,7
 The mechanism of KI is to cause 
heparin release, which aids in suppressing hypersensitivity reactions.
3
 However, KI may also 
inhibit neutrophil chemotaxis.
7 
 Chronic erythema nodosum can progress based on cases presenting with a lesser degree 
of septa thickening and inflammation compared to acute EN. Chronic EN also exhibits 
prominent characteristics of phlebitis (inflammation of veins) and extravasated erythrocytes 
(blood forced out of vessels), not seen in acute EN. However, some cases are misdiagnosed as 
chronic due to the stage of evolution.
11
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CHAPTER 5 
CONCLUSION 
 Erythema nodosum is a rare disorder that affects approximately 1-5 per 100,000 people 
per year. Typically, seen in the female 25-40 year old population, the cause is usually idiopathic; 
however, the most common cause is streptococcal pharyngitis.
2-6,11
 This case demonstrates the 
need for the awareness of a systematic condition that could be present within the athletic 
population. With this information, clinicians can better diagnose and treat erythema nodosum 
along with an awareness of etiologies causing the condition. 
 In this case, due to recent diagnosis of URI and flu-like symptoms, they are assumed to 
be the cause of EN in this athlete. However, it is uncertain and the cause could have been 
idiopathic. Because symptoms worsened after prescribed penicillin the medication may also be a 
trigger of the condition. No further investigation was made to determine the actual cause since 
lesions resolved within two weeks. 
 Clinicians should keep in mind EN can be easily diagnosed and treated by the sports 
medicine staff. In some instances, EN can be a sign of a more serious condition such as 
tuberculosis or sarcoidosis. For this reason it is important for the individual to seek proper 
medical diagnostic testing.   
 14 
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